Download presentation
Presentation is loading. Please wait.
Published byMonica Perry Modified over 9 years ago
1
AMEBIASIS
2
I.Emetine group : e.g. Emetine, dehydroemetine and its resinate. II. Quinoline derivatives: Halogenated hyroxyquinolines: Diiodohydroxyquinoline, iodochloroquine 4 – aminoquinolines: Chloroquine. III. Imidazole derivatives: Metronidazole, tinidazole, secnidazole, ornidazole IV. Antibiotics: Tetracyclines, paromomycin. V. Miscellaneous: Diloxanide furoate and kurchi.
3
Metronidazole: Reductive activation by intracellular transport proteins Reduced by the pyruvate:ferredoxin oxidoreductase system in the mitochondria of obligate anaerobes, which alters its chemical structure. Reduced intermediate particle interacts with intracellular targets — Cytotoxic intermediate particles interact with host cell DNA, resulting in DNA strand breakage and fatal destabilization of the DNA helix
4
Metronidazole Mechanism of action: –Enters bacteria via cell diffusion –Activated via single reduction step by bacteria forms radicals reacts with nucleic acid cell death Spectrum of activity: –Anaerobic bacteria –Microaerophilic bacteria –Protozoa Resistance: –Rare –Mechanism: decreased activation (↓ red ox reaction) of drug
6
Metronidazole Indications: –Anaerobe infections –C. difficile –H. pylori –Bacterial vaginosis –Trichomonas vaginitis –Amebiasis –Giardiasis Drug interactions: –Ethanol –Antacids –CyA/tacrolimus –Lithium –Phenytoin –Rifampin –Warfarin
7
Metronidazole: Uses: 1)T vaginalis 2g single dose, 0.7% gel, 500mg – 1g suppository 2) Amoebiasis 3) Giandaisies 4) Anerobic infections – Bactericides, clostridium, fusobacterium, peptococcus, peptosirgstococcus, Eubacterium, H. pyloris. 5) Polymicrobial infections.
8
6) Prophylaxis of postop mixed bacterial infection 7) Bacterial vaginosis 8) Pseudomembranous colitis 9) Crohns disease with perianal fistulas
9
Metronidazole Distribution into tissue Therapeutic levels: PMNs Unobstructed biliary tract Pancreas CSF Empyema fluid Peritoneal fluid Hepatic abscess Pelvic tissues Vaginal/seminal fluid Adverse Effects: –GI: N, V, epigastric distress –Metallic taste –Darkening of urine –Peripheral neuropathy –Pancreatitis –Hepatitis –Fever –Reversible neutropenia
10
IODOQUINOL EMETINE & DEHYDROEMETINE PAROMOMYCIN SULFATE DILOXANIDE FUROATE
11
Asymptomatic Intestinal Infection Diloxanide500 mgtidx 10d or- Iodoquinol650 mgtidx 21d or- Paromomyin 10 mg/kg tidx 7d
12
Mild to Moderate Intestinal Infection Metronidazole 750mg tid x 10d or- Tinidazole 2g od x 3d Plus- Luminal agent
13
Mild to Moderate Intestinal Infection Alternative: Luminal agent Plus either- Tetracycline 250mg tid x 10d or- Erythromycin 500 mg qid x 10d
14
Severe Intestinal Infection Metronidazole 750mg tid (500mg IV every 6 h) or Tinidazole plus Luminal agent Alternative: Luminal agent plus either Tetracycline or Dehydroemetine 1mg /kg SC/IM x 3-5d
15
Hepatic / Extra intestinal Same as above Alternative: Dehydroemetine 1mg /kg S.C/IM x 3-5d Followed by (liver abscess only) Chloroquine 500mg bd x 2d, then 500mg od x21d Plus Luminal agent
16
PENTAMIDINE: Pnenmocytosis sleeping sickness leishmaniasis Parenteral omebahized powder,
17
LEISHMANIASIS:- 1) Liposonal anyrhotencin 2) Pentroalent antimonish. Sodium stibozhconate meglumine antimonite 3) Miltefosine 4) Pent amidine isethionate 5) paromorycin
18
CUTANEOUS: 1) Pentacalant antimoniab 2) As above 3)Antifungals, allopunol
19
TOPICAL: 1) Iutratesional antimony 2) Paromomycin oint 3) Cryotherapy 4) local heat 5) surgical removal
20
SODIUM STIBOGLUCONATE:- IV / IM. Iutial t1/ 2 – 2 h Terminal t1/ 2 – 24 h 20 mg / kg 1d x 20 d
21
ADR: G.I headache, arthralgia, rash - IM – Stenile abscers - ECG - Hemolytic anemia - LFT, renal effects,
22
NITAZOXANIDE: General. Lanbia C. Parvum E. histohytica A. Iumbricoides Several tapumorns Increase Tizoxamide
23
MILTEFOSINE:- - 2.5mg / kg / d x 28 d - Single dose amp B + 7 – 14 d miltepoine - G. I. - Decrease LFT - Not in Pregnancy - Resistance is a problem. Combination
24
PAROMOMYCIN:- 11mg / kg x 21 d IM - ADR as with AGI
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.